JP2007091673A - Blood circulation promoter, blood-circulating apparatus and blood circulation-promoting medical system - Google Patents

Blood circulation promoter, blood-circulating apparatus and blood circulation-promoting medical system Download PDF

Info

Publication number
JP2007091673A
JP2007091673A JP2005285590A JP2005285590A JP2007091673A JP 2007091673 A JP2007091673 A JP 2007091673A JP 2005285590 A JP2005285590 A JP 2005285590A JP 2005285590 A JP2005285590 A JP 2005285590A JP 2007091673 A JP2007091673 A JP 2007091673A
Authority
JP
Japan
Prior art keywords
blood
blood circulation
mover
blood vessel
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005285590A
Other languages
Japanese (ja)
Inventor
Tadahiro Sasaki
忠寛 佐々木
Yujiro Naruse
雄二郎 成瀬
Kazuhide Abe
和秀 阿部
Risa Sugiura
理砂 杉浦
Kazuhiro Henmi
和弘 逸見
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toshiba Corp
Original Assignee
Toshiba Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toshiba Corp filed Critical Toshiba Corp
Priority to JP2005285590A priority Critical patent/JP2007091673A/en
Publication of JP2007091673A publication Critical patent/JP2007091673A/en
Pending legal-status Critical Current

Links

Images

Abstract

<P>PROBLEM TO BE SOLVED: To provide a blood circulation promoter, a blood-circulating apparatus and blood circulation- promoting medical system, free from load of patients by catheter surgery and capable of removing cause of vasoconstriction. <P>SOLUTION: The blood circulation promoter comprises a mover 2 self-propelling by irradiation of light and having particle diameter with a nanometer order and a dispersant 3 for dispersing the mover. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

本発明は、 血液循環促進剤、血液循環装置および血液循環促進医療システムに関する。   The present invention relates to a blood circulation promoting agent, a blood circulation device, and a blood circulation promoting medical system.

現在、食生活の変化に伴い動物性脂肪等の摂取が増加する一方、運動不足等により、コレステロールや中性脂肪が体内に過度に蓄積される成人の割合が増加しつつある。それに伴って血液中のコレステロール、中心脂肪等の割合が増加し、その結果、血管の狭窄を発生させ、心筋梗塞、脳梗塞等の命に関わる疾患の発生の原因となる。これらの疾患の治療方法としては、現在では、低侵襲手術方法として、血管内にカテーテルを挿入し、レーザー照射（例えば、特許文献１）、バルーン（例えば、特許文献２）、薬剤の投与（例えば、特許文献３）等により血管の狭窄の原因を取り除く方法が行われている。現在では治療に用いられるカテーテル径の小型化が進んでおり、患者の負担がより低減される方向に技術開発が進められている。
特開平５−６４６６８号 特開２００５−１６０５３６号 特開２００１−２５２３５４号 Currently, the intake of animal fat and the like increases with changes in dietary habits, while the proportion of adults who excessively accumulate cholesterol and neutral fat due to lack of exercise is increasing. Along with this, the proportion of cholesterol, central fat, etc. in the blood increases, and as a result, stenosis of blood vessels occurs, causing the occurrence of life-related diseases such as myocardial infarction and cerebral infarction. Currently, as a method for treating these diseases, as a minimally invasive surgical method, a catheter is inserted into a blood vessel, laser irradiation (for example, Patent Document 1), balloon (for example, Patent Document 2), administration of a drug (for example, (Patent Document 3) etc., a method for removing the cause of stenosis of blood vessels has been performed. At present, the diameter of the catheter used for treatment is being reduced, and technological development is proceeding in a direction that further reduces the burden on the patient.
Japanese Patent Laid-Open No. 5-64668 JP 2005-160536 A JP 2001-252354 A

しかしながら、一方で、カテーテルを用いた手術では、約５％程度の失敗、すなわち、カテーテル手術の実施による患者の死亡例があるとされている。これは、血管の狭窄の原因を取り除く際に、その部位から剥がれたコレステロール等が、塊のまま血管内を流れ、その塊が別の血管（例えば、脳に向かう大動脈等）を詰まらせてしまい、別の疾患（例えば、脳梗塞）を引き起こす可能性があるからである。   However, on the other hand, in the operation using the catheter, it is said that there are about 5% failure, that is, there are cases of death of the patient due to the catheter operation. This is because when the cause of the stenosis of the blood vessel is removed, cholesterol or the like peeled off from the site flows in the blood vessel as a lump, and the lump clogs another blood vessel (for example, the aorta toward the brain). This is because it may cause another disease (for example, cerebral infarction).

本発明はかかる実情に鑑みてなされたものであり、カテーテル手術等による患者の負担が無く、血管の狭窄の原因を取り除くことができる血液循環促進剤、血液循環装置および血液循環促進医療システムを提供することを目的とする。   The present invention has been made in view of such circumstances, and provides a blood circulation promoter, a blood circulation device, and a blood circulation promotion medical system that can eliminate the cause of stenosis of blood vessels without burdening the patient due to catheter surgery or the like. The purpose is to do.

本発明に関わる血液循環促進剤は、光の照射により自走するナノメートルオーダーの粒径を有する可動子と、前記可動子を分散させるための分散剤と、を備えることを特徴とする。   The blood circulation promoter according to the present invention is characterized by comprising a mover having a particle size of nanometer order that is self-propelled by light irradiation, and a dispersant for dispersing the mover.

また、本発明に関わる血液循環装置は、生体の血液を採取する血液採取手段と、採取された血液を循環させる血液循環手段と、前記血液循環手段に光の照射により自走するナノメートルオーダーの粒径を有する可動子が分散された血液循環促進剤を供給する血液循環促進剤供給手段と、前記血液循環促進剤が供給された血液に光を照射する光照射手段と、前記光照射手段で照射された血液を前記生体に注射する血液注射手段と、を備えたことを特徴とする。   The blood circulation apparatus according to the present invention includes a blood collection means for collecting blood from a living body, a blood circulation means for circulating the collected blood, and a nanometer-order that is self-propelled by light irradiation to the blood circulation means. A blood circulation promoting agent supplying means for supplying a blood circulation promoting agent in which a mover having a particle size is dispersed, a light irradiating means for irradiating light to the blood supplied with the blood circulation promoting agent, and the light irradiating means. Blood injection means for injecting the irradiated blood into the living body.

また、本発明に関わる血液循環促進医療システムは、光の照射により自走するナノメートルオーダーの粒径を有する可動子が分散された血液循環促進剤と、前記血液循環促進剤に含まれる可動子に光エネルギーを供給する光照射装置と、を備える。   The blood circulation promoting medical system according to the present invention includes a blood circulation promoting agent in which a movable body having a particle size of nanometer order that is self-propelled by light irradiation is dispersed, and a movable body contained in the blood circulation promoting agent. A light irradiation device for supplying light energy to the light source.

カテーテル手術等による患者の負担が無く、血管の狭窄の原因を取り除くことが可能な血液循環促進剤、血液循環装置および血液循環促進医療システムを提供することができる。   It is possible to provide a blood circulation promoter, a blood circulation device, and a blood circulation promotion medical system that can remove the cause of stenosis of blood vessels without burdening the patient due to catheter surgery or the like.

以下、本発明の実施形態について、図面を用いて説明する。なお、以下の説明において、略同一の機能及び構成を有する構成要素については、同一符号を付する。   Hereinafter, embodiments of the present invention will be described with reference to the drawings. In the following description, components having substantially the same functions and configurations are denoted by the same reference numerals.

図１に、本発明に関わる血液循環促進剤を説明する概念図を示す。   FIG. 1 is a conceptual diagram illustrating a blood circulation promoting agent according to the present invention.

本発明に関わる血液循環促進剤１は、図１に示すように、ナノメートルオーダーの粒径を有する可動子２と、可動子２を分散させるための分散剤３とを備えている。   As shown in FIG. 1, the blood circulation promoting agent 1 according to the present invention includes a mover 2 having a particle size on the order of nanometers, and a dispersant 3 for dispersing the mover 2.

可動子２は、外部から光を照射すると特定の方向に自走する特性を備えている微粒子体であり、半導体特性を有する材料、例えば、シリコンで構成されている。   The mover 2 is a fine particle body having a characteristic of self-running in a specific direction when irradiated with light from the outside, and is made of a material having semiconductor characteristics, for example, silicon.

可動子２の粒径は、図１に示すように、数十ｎｍ〜数百ｎｍ程度のナノメートルオーダーで構成されている。可動子２の粒径がミクロンメートルオーダー以上の粒径で構成されている場合は、その可動子２が生体の血管を流れる際に、体内に存在する血管のうち、特にその径が細い毛細血管等を詰まらせてしまう可能性があるため好ましくない。   As shown in FIG. 1, the particle diameter of the mover 2 is in the order of nanometers of about several tens of nanometers to several hundreds of nanometers. When the mover 2 has a particle size of a micrometer order or more, when the mover 2 flows through the blood vessel of the living body, among the blood vessels existing in the body, the capillary vessel having a particularly small diameter. This is not preferable because it may clog the like.

可動子２は、球体、又は、楕円体の形状を有していることが好ましい。可動子２の形状が、球体、又は、楕円体以外の形状、例えば、鋭角、又は、鈍角の尖った部分を有している多角形である場合は、その尖った部分が生体の血管内の内壁を傷つけてしまう可能性があるため好ましくない。   The mover 2 preferably has a spherical or elliptical shape. When the shape of the mover 2 is a shape other than a sphere or an ellipsoid, for example, a polygon having a sharp or obtuse sharp point, the sharp part is inside the blood vessel of the living body. This is not preferable because the inner wall may be damaged.

なお、可動子２は、前述したように、ナノメートルオーダーの粒径を備えているため、可動子２同士で凝縮してしまう傾向を有している。そのため可動子２は分散剤３に分散されている。   In addition, since the needle | mover 2 is provided with the particle size of a nanometer order as mentioned above, it has the tendency for the needle | mover 2 to condense with each other. Therefore, the mover 2 is dispersed in the dispersant 3.

分散剤３は、人間を治療する医薬品であって、弱アルカリ性、例えば、ｐＨ７．１〜８．０である液状の医薬品で構成されている。これにより可動子２は、可動子２同士で凝縮されずに、分散剤３内でそれぞれ数十ｎｍ〜数百ｎｍ程度の粒径の微粒子体として存在することができる。   Dispersant 3 is a medicine for treating humans, and is composed of a liquid medicine having a weak alkalinity, for example, pH 7.1 to 8.0. Thereby, the mover 2 can exist as fine particles having a particle diameter of about several tens nm to several hundreds nm in the dispersant 3 without being condensed between the movers 2.

分散剤３には、抗狭心症薬、血液凝固阻止薬、強心剤等の心臓疾患用の治療法で用いられる液状の心臓疾患用医薬品が含まれていることがより好ましい。これにより、心臓疾患用薬品としての従来の心臓疾患の治療の効果と、可動子２の存在による血液循環促進剤としての効果も加わり、より効果の高い心臓疾患用医薬品としての血液循環促進剤を提供することができる。   More preferably, the dispersing agent 3 contains a liquid heart disease drug used in a heart disease treatment method such as an antianginal drug, a blood coagulation inhibitor, and a cardiotonic agent. As a result, the effect of conventional heart disease treatment as a heart disease drug and the effect as a blood circulation promoter due to the presence of the mover 2 are added, and a blood circulation promoter as a more effective heart disease drug is added. Can be provided.

次に、本発明の可動子２が分散された血液循環促進剤１を生体に使用した場合の効果を説明する。図２から図４は、本発明に関わる血液循環促進剤１を生体に注射した時の生体の血管内の状態を説明する概念図である。   Next, the effect when the blood circulation promoter 1 in which the mover 2 of the present invention is dispersed is used in a living body will be described. FIG. 2 to FIG. 4 are conceptual diagrams for explaining the state in the blood vessel of the living body when the blood circulation promoting agent 1 according to the present invention is injected into the living body.

可動子２が分散された血液循環促進剤１を注射器、又は、点滴等により血管内に注射すると、血管内には、図２に示すように血液と共に、可動子２が血液の流れにのって血管内を循環する。   When the blood circulation promoting agent 1 in which the movable element 2 is dispersed is injected into the blood vessel by a syringe or infusion, the movable element 2 follows the blood flow in the blood vessel together with blood as shown in FIG. Circulate in the blood vessels.

なお、可動子２は、図２に示すように、血液内に存在する白血球（１０〜１５μｍ）、赤血球（約８μｍ）、血小板（２〜５μｍ）等よりもはるかに小さいナノメートルオーダーの粒径を備えているため、可動子２が注入されて血管内を流れたとしても通常の血液の流れ自体に悪影響を及ぼすことはない。   As shown in FIG. 2, the mover 2 has a particle size on the order of nanometers much smaller than white blood cells (10 to 15 μm), red blood cells (about 8 μm), platelets (2 to 5 μm), etc. present in blood. Therefore, even if the mover 2 is injected and flows through the blood vessel, the normal blood flow itself is not adversely affected.

また、個人差は存在するが、一般的な成人の血管の直径は、大動脈でおよそ２．５ｃｍ、動脈でおよそ４ｍｍ、細動脈でおよそ３０μｍ、毛細血管でおよそ数μｍ〜１０μｍであるため、ナノメートルオーダーの粒径で構成されている可動子２が注入されて血管内を流れたとしても、毛細血管を含むすべての血管が、血液中の可動子２によって詰まる等の不具合は発生しない。つまり、体内の血液の流れを阻害することはない。   Although there are individual differences, the diameter of a typical adult blood vessel is approximately 2.5 cm in the aorta, approximately 4 mm in the artery, approximately 30 μm in the arteriole, and approximately several μm to 10 μm in the capillary. Even if the movable element 2 configured with a particle size of the metric order is injected and flows through the blood vessel, all the blood vessels including the capillary blood vessels do not cause a problem such as clogging by the movable element 2 in the blood. In other words, it does not hinder the blood flow in the body.

可動子２が血液中に存在すると、血液の血流にのって、可動子２は、体内を循環していき、例えば、図３に示すように、血管の内壁に付着したコレステロール４が存在している血管の主要部に可動子２がさしかかった場合には、可動子２は、血流の流れの運動エネルギーを備えた状態でコレステロール４に接触する。接触した可動子２は、徐々に、コレステロール４を破壊し、削り取っていく機能を備えている。このように、可動子２は、血管内のコレステロール４等を徐々に破壊していくため、前述したように、血管内の内壁に付着したコレステロール４等が大きい塊のまま剥がれる心配がなく、その塊が別の血管（例えば、脳に向かう大動脈等）を詰まらせるという最悪の事態は発生することはない。   When the mover 2 is present in the blood, the mover 2 circulates in the body along the blood flow. For example, as shown in FIG. 3, there is cholesterol 4 attached to the inner wall of the blood vessel. When the mover 2 reaches the main part of the blood vessel that is in contact with the cholesterol 4, the mover 2 comes into contact with the cholesterol 4 with the kinetic energy of the blood flow. The movable element 2 in contact has a function of gradually destroying and scraping off the cholesterol 4. Thus, since the mover 2 gradually destroys cholesterol 4 and the like in the blood vessel, as described above, there is no fear that the cholesterol 4 or the like attached to the inner wall of the blood vessel is peeled off as a large lump. The worst case where a mass clogs another blood vessel (eg, an aorta going to the brain) does not occur.

加えて、可動子２は、長い年月が経過すると血管内の血液中に溶解してしまう性質を備えている。血液は、その４５％が水分で構成されていると言われているが、人間の日常の食事等により、血液は酸性、または、アルカリ性に変化する。なお、可動子２は、半導体材料で構成されているため、長い年月をかけて血液内で酸エッチング、または、アルカリエッチングされ、数年で完全に血液内に溶解してしまう特性も備えている。よって、血液中に存在している可動子２は、将来的に、血液中に溶解してしまうため、治療終了後、可動子２を、血液中から取り除く必要はない。   In addition, the mover 2 has a property of being dissolved in blood in the blood vessel after a long period of time. It is said that 45% of blood is composed of water, but blood changes to acidity or alkalinity due to daily human diet. In addition, since the mover 2 is made of a semiconductor material, it has a characteristic of being dissolved in the blood completely in a few years after being acid-etched or alkali-etched in the blood over a long period of time. Yes. Therefore, since the mover 2 existing in the blood will be dissolved in the blood in the future, it is not necessary to remove the mover 2 from the blood after the treatment is completed.

このように、本発明に関わる血液循環促進剤は、血液循環促進剤内に含まれるナノメートルオーダーの粒径を有する可動子によって、血管内部に付着したコレステロール等を徐々に剥離させる効果を備えているため、カテーテル等の手術を行う必要がなく、血管の狭窄の原因を取り除くことが可能となる。   As described above, the blood circulation promoter according to the present invention has an effect of gradually peeling cholesterol and the like attached to the inside of a blood vessel by a mover having a particle size of nanometer order contained in the blood circulation promoter. Therefore, it is not necessary to perform an operation such as a catheter, and the cause of stenosis of the blood vessel can be removed.

次に、本発明に関わる血液循環促進医療システムを説明する。図４は、本発明に関わる血液循環促進医療システムを説明する概念図である。   Next, a blood circulation promotion medical system according to the present invention will be described. FIG. 4 is a conceptual diagram illustrating a blood circulation promoting medical system according to the present invention.

本発明に関わる血液循環促進医療システムは、光の照射により自走するナノメートルオーダーの粒径を有する可動子が分散された血液循環促進剤と、血液循環促進剤に含まれる可動子に光エネルギーを供給する光照射装置と、を備えている。   The blood circulation promoting medical system according to the present invention includes a blood circulation promoting agent in which a mover having a particle size of nanometer order that is self-propelled by irradiation of light is dispersed, and light energy in a mover contained in the blood circulation promoting agent. A light irradiation device for supplying

具体的には、図４に示すように、光の照射により自走するナノメートルオーダーの粒径を有する可動子２が分散された血液循環促進剤１を注射器、又は、点滴等により生体内に注射すると共に、更に、図示しない光照射装置を用いて、生体の血管に光５を照射することで、血液中を流れている可動子２に、可動子２自身が自走する光エネルギーを供給し、可動子２を血流の方向に自走させる。これによって、通常の血流の流れをより加速させることが可能となると共に、血管の内壁に付着しているコレステロール等を削り取る場合でも、血流の流れの運動エネルギーに加えて、可動子２自身が自走する運動エネルギーが加えられるため、より効率的にコレステロール等を削り取ることが可能となる。   Specifically, as shown in FIG. 4, the blood circulation promoter 1 in which the movable element 2 having a particle size of nanometer order that is self-propelled by light irradiation is dispersed is injected into the living body by a syringe or infusion. In addition to the injection, the light 5 is irradiated to the blood vessel of the living body using a light irradiation device (not shown), thereby supplying the movable element 2 flowing in the blood with the light energy that the movable element 2 itself runs. Then, the movable element 2 is self-propelled in the direction of blood flow. This makes it possible to further accelerate the normal blood flow, and even when removing cholesterol or the like adhering to the inner wall of the blood vessel, in addition to the kinetic energy of the blood flow, the mover 2 itself Since kinetic energy for self-running is added, cholesterol and the like can be scraped off more efficiently.

なお、図４に示すような、生体に光を照射する光照射装置としては、図５に示すように、例えば、腕輪６に設けられた発光ダイオード７を備えた光照射装置８で構成されている。これらの光照射装置８に備えられている発光ダイオード７の部分を、腕の動脈、又は、静脈の部分に接触させて、生体に光を照射することで、図４に示すように、血液中を流れる可動子２に光エネルギーを供給することが可能となる。   In addition, as shown in FIG. 5, as a light irradiation apparatus which irradiates light to a biological body as shown in FIG. 4, it is comprised by the light irradiation apparatus 8 provided with the light emitting diode 7 provided in the bracelet 6, for example. Yes. The light emitting diode 7 provided in these light irradiation devices 8 is brought into contact with the arteries or veins of the arm and irradiated on the living body, as shown in FIG. It becomes possible to supply light energy to the movable element 2 that flows through.

光照射装置８から生体に照射する光５は、可視光、又は、赤外光を用いることが好ましい。その他の光（例えば、紫外光等）を照射する場合は、生体に悪影響を及ぼすため好ましくない。   It is preferable to use visible light or infrared light as the light 5 irradiated to the living body from the light irradiation device 8. Irradiation with other light (for example, ultraviolet light or the like) is not preferable because it adversely affects the living body.

なお、前述した光照射装置８は、図５に限定されるものではなく、首輪、指輪等で構成されていてもよい。さらに、発光ダイオード７は、複数、例えば、腕輪６の内壁全体に備えてもよく、腕全体に光を照射することができる構成としてもよい。さらに、平面状の基材に発光ダイオード７を取り付ける構成としてもよい。   In addition, the light irradiation apparatus 8 mentioned above is not limited to FIG. 5, You may be comprised by the collar, the ring, etc. Further, a plurality of light emitting diodes 7 may be provided, for example, on the entire inner wall of the bracelet 6, or the entire arm may be irradiated with light. Furthermore, it is good also as a structure which attaches the light emitting diode 7 to a planar base material.

このように、本発明に関わる血液循環促進医療システムは、ナノメートルオーダーの粒径を有する可動子が分散された血液循環促進剤を血管内に注射すると共に、生体外部から光照射装置８等により生体内に光を照射することで、血液循環促進剤の効果をより高めることができる。   As described above, the blood circulation promoting medical system according to the present invention injects a blood circulation promoting agent in which a mover having a particle size of nanometer order is dispersed into a blood vessel, and from the outside of the living body by a light irradiation device 8 or the like. By irradiating the living body with light, the effect of the blood circulation promoter can be further enhanced.

次に、本発明に関わる血液循環装置を説明する。図６は、本発明に関わる血液循環装置を説明する概念図である。   Next, the blood circulation apparatus according to the present invention will be described. FIG. 6 is a conceptual diagram illustrating a blood circulation apparatus according to the present invention.

本発明に関わる血液循環装置１０は、血液採取部１１と、血液循環部１２と、血液循環促進剤供給部１３と、光照射部１４と、血液注射部１５とを備えている。   A blood circulation device 10 according to the present invention includes a blood collection unit 11, a blood circulation unit 12, a blood circulation promoter supply unit 13, a light irradiation unit 14, and a blood injection unit 15.

血液採取部１１は、生体から血液を採取する血液採取手段を備えており、例えば、注射器１１ａで構成されている。   The blood collection unit 11 includes blood collection means for collecting blood from a living body, and includes, for example, a syringe 11a.

血液循環部１２は、血液採取部１１で採取した血液を循環させる血液循環手段を備えており、例えば、血液採取部１１で採取した血液を循環させるための細管１２ａと、細管１２ａ内の血液を循環させる血液循環装置１２ｂとで構成されている。   The blood circulation unit 12 includes blood circulation means for circulating the blood collected by the blood collection unit 11. For example, the blood circulation unit 12 circulates the blood collected by the blood collection unit 11 and the blood in the capillary 12a. It is comprised with the blood circulation apparatus 12b to circulate.

血液循環促進剤供給部１３は、血液循環部１２の細管１２ａに光の照射により自走するナノメートルオーダーの粒径を有する可動子が分散された血液循環促進剤を供給する血液循環促進剤供給手段を備えており、例えば、血液循環促進剤を収容する収容部１３ａと、血液循環部１２の細管１２ａに血液循環促進剤を供給するための細管１３ｂで構成されている。   The blood circulation promoting agent supply unit 13 supplies the blood circulation promoting agent for supplying the blood circulation promoting agent in which the movable elements having a particle size of nanometer order that are self-propelled by light irradiation to the thin tubes 12a of the blood circulating unit 12 are dispersed. For example, it is composed of a storage portion 13a for storing a blood circulation promoter and a thin tube 13b for supplying the blood circulation promoter to the thin tube 12a of the blood circulation portion 12.

光照射部１４は、血液循環部１２の細管１２ａに光を照射することで、血液循環促進剤が供給された血液に光を照射する光照射手段を備えており、例えば、発光ダイオード１４ａと、発光ダイオード１４ａを固定する固定基材１４ｂで構成されている。   The light irradiation unit 14 includes light irradiation means for irradiating light to the blood supplied with the blood circulation promoting agent by irradiating light to the thin tube 12a of the blood circulation unit 12, for example, a light emitting diode 14a, It is comprised by the fixed base material 14b which fixes the light emitting diode 14a.

血液注入部１５は、光照射部１４で光を照射した血液を、生体に注射するための血液注射手段を備えており、例えば、注射器１５ａで構成されている。   The blood injection unit 15 includes blood injection means for injecting the blood irradiated with light by the light irradiation unit 14 into a living body, and is constituted by, for example, a syringe 15a.

このように、本発明に関わる血液循環装置は、生体から血液を採取して、採取した血液に本発明に関わる血液循環促進剤を供給し、血液循環促進剤を供給した血液に対して、光を照射してから生体内に戻すことで、血液循環促進剤内に含まれる可動子が光エネルギーを備えた状態で、血液内に供給することができる。   As described above, the blood circulation apparatus according to the present invention collects blood from a living body, supplies the collected blood with the blood circulation promoter according to the present invention, and applies light to the blood supplied with the blood circulation promoter. Can be supplied into the blood in a state in which the mover included in the blood circulation promoter is provided with light energy.

以下に実施例を説明するが、本発明の主旨を超えない限り、本発明は以下に掲載される実施例に限定されるものでない。   Examples will be described below, but the present invention is not limited to the examples described below unless the gist of the present invention is exceeded.

（実施例１）
図７に示すように、循環器２０に、全長３ｍ、直径４ｍｍの人工血管２１を接続して、常に、人工血管２１内に溶媒を循環させる簡易的な溶媒循環装置を作成した。その後、人工血管２１の一部を切断し、その内壁に、コレステロールと同じ物質で構成された大きさが１ｍｍの塊２２を、接着剤を用いて接着させて、もとの位置に縫合させた。 Example 1
As shown in FIG. 7, an artificial blood vessel 21 having a total length of 3 m and a diameter of 4 mm was connected to the circulator 20 to create a simple solvent circulation device that always circulates the solvent in the artificial blood vessel 21. Thereafter, a part of the artificial blood vessel 21 was cut, and a lump 22 made of the same substance as cholesterol and having a size of 1 mm was adhered to the inner wall using an adhesive and sutured to the original position. .

その後、人工血管２１内に溶媒として人工血液を流し込み、循環の流量を安定させた後、分散剤に粒径が１０〜５０ｎｍの楕円体のシリコンで構成された可動子を分散させた血液循環促進剤を人工血管２１内に注射器で注入して、７２時間人工血液を循環させた。   Thereafter, artificial blood is poured into the artificial blood vessel 21 as a solvent to stabilize the circulation flow rate, and then blood circulation is promoted by dispersing a movable element made of ellipsoidal silicon having a particle size of 10 to 50 nm in the dispersant. The agent was injected into the artificial blood vessel 21 with a syringe, and the artificial blood was circulated for 72 hours.

７２時間経過後、人工血液の循環をやめて、人工血管２１内の人工血液を排出した後、人工血管２１の内壁に接着させた塊２２を採取し、その大きさを計測して、塊２２の大きさの変化を確認した。その結果、塊２２の大きさは、０．９７ｍｍ程度に減少しており、微小ではあるが、明らかに、塊２２が小さくなっていることが確認された。   After 72 hours, the circulation of the artificial blood is stopped and the artificial blood in the artificial blood vessel 21 is discharged. Then, the lump 22 adhered to the inner wall of the artificial blood vessel 21 is collected, and the size of the lump 22 is measured. The change in size was confirmed. As a result, the size of the lump 22 was reduced to about 0.97 mm, and although it was very small, it was clearly confirmed that the lump 22 was small.

（実施例２）
図８に示すように、循環器２０に、全長３ｍ、直径４ｍｍの人工血管２１を接続して、常に、人工血管２１内に溶媒を循環させる簡易的な溶媒循環装置を作成した。その後、人工血管２１の一部を切断し、その内壁に、コレステロールと同じ物質で構成された大きさが１ｍｍの塊２２を、接着剤を用いて接着させて、もとの位置に縫合させた。 (Example 2)
As shown in FIG. 8, an artificial blood vessel 21 having a total length of 3 m and a diameter of 4 mm was connected to the circulator 20 to create a simple solvent circulation device that always circulates the solvent in the artificial blood vessel 21. Thereafter, a part of the artificial blood vessel 21 was cut, and a lump 22 made of the same substance as cholesterol and having a size of 1 mm was adhered to the inner wall using an adhesive and sutured to the original position. .

その後、人工血管２１内に溶媒として人工血液を流し込み、循環の流量を安定させた後、分散剤に粒径が１０〜５０ｎｍの楕円体のシリコンで構成された可動子を分散させた血液循環促進剤を人工血管２１内に注射器で注入すると共に、人工血管２１の一部に、基材２３に固定された発光ダイオード２４から可視光を照射して、７２時間人工血液を循環させた。   Thereafter, artificial blood is poured into the artificial blood vessel 21 as a solvent to stabilize the circulation flow rate, and then blood circulation is promoted by dispersing a movable element made of ellipsoidal silicon having a particle size of 10 to 50 nm in the dispersant. The agent was injected into the artificial blood vessel 21 with a syringe, and a part of the artificial blood vessel 21 was irradiated with visible light from the light emitting diode 24 fixed to the base material 23 to circulate the artificial blood for 72 hours.

７２時間経過後、人工血液の循環をやめて、人工血管２１内の人工血液を排出した後、人工血管２１の内壁に接着させた塊２２を採取し、大きさを計測して、塊２２の大きさの変化を確認した。その結果、塊２２の大きさは、０．９４ｍｍ程度に減少しており、明らかに、塊２２が小さくなっていることが確認された。   After 72 hours, the circulation of the artificial blood is stopped, the artificial blood in the artificial blood vessel 21 is discharged, the lump 22 adhered to the inner wall of the artificial blood vessel 21 is collected, the size is measured, and the size of the lump 22 is measured. I confirmed the change. As a result, the size of the lump 22 was reduced to about 0.94 mm, and it was clearly confirmed that the lump 22 was small.

（実施例３）
図９に示すように、循環器２０に、全長３ｍ、直径４ｍｍの人工血管２１を接続して、常に、人工血管２１内に溶媒を循環させる簡易的な溶媒循環装置を作成した。その後、人工血管２１の一部を切断し、その内壁に、コレステロールと同じ物質で構成された大きさが１ｍｍの塊２２を、接着剤を用いて接着させて、もとの位置に縫合させた。さらに、直径３０μｍの人工血管２５を、複数本、縫合してバイパスを作り、仮想的な毛細血管を作製した。 (Example 3)
As shown in FIG. 9, an artificial blood vessel 21 having a total length of 3 m and a diameter of 4 mm was connected to the circulator 20 to create a simple solvent circulation device that always circulates the solvent in the artificial blood vessel 21. Thereafter, a part of the artificial blood vessel 21 was cut, and a lump 22 made of the same substance as cholesterol and having a size of 1 mm was adhered to the inner wall using an adhesive and sutured to the original position. . Further, a plurality of artificial blood vessels 25 having a diameter of 30 μm were sutured to create a bypass, thereby producing a virtual capillary blood vessel.

その後、人工血管２１内に人工血液を流し込み、循環の流量を安定させた後、分散剤に粒径が１０〜５０ｎｍの楕円体のシリコンで構成された可動子を分散させた血液循環促進剤を人工血管２１内に注射器で注入して、１４４時間人工血液を循環させた。   After that, artificial blood is poured into the artificial blood vessel 21 to stabilize the circulation flow rate, and then a blood circulation promoting agent in which a movable element made of ellipsoidal silicon having a particle size of 10 to 50 nm is dispersed in the dispersing agent. Artificial blood was circulated for 144 hours by injecting into the artificial blood vessel 21 with a syringe.

１４４時間経過後、人工血液の循環をやめて、人工血管２１内の人工血液を排出した後、人工血管２１の内壁に接着させた塊２２を採取し、その大きさを計測して、塊２２の大きさの変化を確認すると共に、直径３０μｍの人工血管２５を縫合した部分の人工血管２５の接合部２６の詰まり程度を目視にて確認した。その結果、塊２２の大きさは、０．９３ｍｍ程度に減少しており、明らかに、塊２２が小さくなっていることが確認された。また、すべての接合部２６においてコレステロール等による詰まりは確認されなかった。   After 144 hours, the circulation of the artificial blood is stopped and the artificial blood in the artificial blood vessel 21 is discharged. Then, the lump 22 adhered to the inner wall of the artificial blood vessel 21 is collected, and the size of the lump 22 is measured. While confirming the change in size, the degree of clogging of the joint portion 26 of the artificial blood vessel 25 where the artificial blood vessel 25 having a diameter of 30 μm was stitched was visually confirmed. As a result, the size of the lump 22 was reduced to about 0.93 mm, and it was clearly confirmed that the lump 22 was small. Moreover, clogging due to cholesterol or the like was not confirmed in all the joint portions 26.

（実施例４）
図１０に示すように、循環器２０に、全長３ｍ、直径４ｍｍの人工血管２１を接続して、常に、人工血管２１内に溶媒を循環させる簡易的な溶媒循環装置を作成した。その後、人工血管２１の一部を切断し、その内壁に、コレステロールと同じ物質で構成された大きさが１ｍｍの塊２２を、接着剤を用いて接着させて、もとの位置に縫合させた。さらに、直径３０μｍの人工血管２５を、複数本、縫合してバイパスを作り、仮想的な毛細血管を作製した。 Example 4
As shown in FIG. 10, a simple solvent circulation device for always circulating the solvent in the artificial blood vessel 21 was created by connecting the artificial blood vessel 21 having a total length of 3 m and a diameter of 4 mm to the circulator 20. Thereafter, a part of the artificial blood vessel 21 was cut, and a lump 22 made of the same substance as cholesterol and having a size of 1 mm was adhered to the inner wall using an adhesive and sutured to the original position. . Further, a plurality of artificial blood vessels 25 having a diameter of 30 μm were sutured to create a bypass, thereby producing a virtual capillary blood vessel.

その後、人工血管２１内に人工血液を流し込み、循環の流量を安定させた後、分散剤に粒径が１０〜５０ｎｍの楕円体のシリコンで構成された可動子を分散させた血液循環促進剤を人工血管２１内に注射器で注入すると共に、人工血管２１の一部に、基材２３に固定された発光ダイオード２４から可視光を照射して、１４４時間人工血液を循環させた。   After that, artificial blood is poured into the artificial blood vessel 21 to stabilize the circulation flow rate, and then a blood circulation promoting agent in which a movable element made of ellipsoidal silicon having a particle size of 10 to 50 nm is dispersed in the dispersing agent. While inject | pouring into the artificial blood vessel 21 with a syringe, visible light was irradiated to a part of the artificial blood vessel 21 from the light emitting diode 24 fixed to the base material 23, and artificial blood was circulated for 144 hours.

１４４時間経過後、人工血液の循環をやめて、人工血管２１内の人工血液を排出した後、人工血管２１の内壁に接着させた塊２２を採取し、その大きさを計測して、塊２２の大きさの変化を確認するとともに、直径３０μｍの人工血管２５を縫合した部分の人工血管２５の接合部２６の詰まり程度を目視にて確認した。その結果、塊２２の大きさは、０．９０ｍｍ程度に減少しており、明らかに、塊２２が小さくなっていることが確認された。また、すべての接合部２６においてコレステロール等による詰まりは確認されなかった。   After 144 hours, the circulation of the artificial blood is stopped and the artificial blood in the artificial blood vessel 21 is discharged. Then, the lump 22 adhered to the inner wall of the artificial blood vessel 21 is collected, and the size of the lump 22 is measured. While confirming the change in size, the degree of clogging of the joint portion 26 of the artificial blood vessel 25 in the portion where the artificial blood vessel 25 having a diameter of 30 μm was sutured was visually confirmed. As a result, the size of the lump 22 was reduced to about 0.90 mm, and it was clearly confirmed that the lump 22 was small. Moreover, clogging due to cholesterol or the like was not confirmed in all the joint portions 26.

（実施例５）
微量の抗狭心症薬（ニトログリセリン）を混ぜた心臓疾患用医薬品に粒径が１０〜５０ｎｍの楕円体のシリコンで構成された可動子を分散させた血液循環促進剤を用いて、その他は、実施例４と同様な条件にて、１４４時間人工血液を循環させて、塊２２の大きさの変化を確認するとともに、直径３０μｍの人工血管２５を縫合した部分の人工血管２５の接合部２６の詰まり程度を目視にて確認した。その結果、塊２２の大きさは、０．８５ｍｍ程度に減少しており、明らかに、塊２２が小さくなっていることが確認された。また、すべての接合部２６においてコレステロール等による詰まりは確認されなかった。 (Example 5)
Using a blood circulation promoting agent in which a mover composed of ellipsoidal silicon with a particle size of 10 to 50 nm is dispersed in a heart disease drug mixed with a small amount of anti-anginal drug (nitroglycerin), The artificial blood was circulated for 144 hours under the same conditions as in Example 4 to confirm the change in the size of the mass 22, and at the joint 26 of the artificial blood vessel 25 where the artificial blood vessel 25 having a diameter of 30 μm was sutured. The degree of clogging was visually confirmed. As a result, the size of the lump 22 was reduced to about 0.85 mm, and it was clearly confirmed that the lump 22 was small. Moreover, clogging due to cholesterol or the like was not confirmed in all the joint portions 26.

（実施例６）
図１１に示すように、循環器２０に、全長３ｍ、直径４ｍｍの人工血管２１を接続して、常に、人工血管２１内に溶媒を循環させる簡易的な溶媒循環装置を作成した。その後、人工血管２１の一部を切断し、その内壁に、コレステロールと同じ物質で構成された大きさが１ｍｍの塊２２を、接着剤を用いて接着させて、もとの位置に縫合させた。 (Example 6)
As shown in FIG. 11, a simple solvent circulation device that always circulates a solvent in the artificial blood vessel 21 was created by connecting an artificial blood vessel 21 having a total length of 3 m and a diameter of 4 mm to the circulator 20. Thereafter, a part of the artificial blood vessel 21 was cut, and a lump 22 made of the same substance as cholesterol and having a size of 1 mm was adhered to the inner wall using an adhesive and sutured to the original position. .

その後、人工血管２１内に溶媒として人工血液を流し込み、循環の流量を安定させた後、塊２２を接着して縫合させた人工血管２１の循環方向上流部に、図１１に示すように、血液循環装置１０を接続し、人工血管２１内を流れる人工血液の一部を血液循環装置１０内に流し込み、血液循環促進剤供給部１３から、人工血液内に血液循環促進剤を供給すると共に、光照射部１４で、血液循環促進剤を供給した人工血液に可視光を照射して、１４４時間人工血液を循環させた。   Thereafter, artificial blood is poured into the artificial blood vessel 21 as a solvent to stabilize the circulation flow rate, and then blood is attached to the upstream portion in the circulation direction of the artificial blood vessel 21 to which the mass 22 is bonded and sutured, as shown in FIG. The circulation device 10 is connected, a part of the artificial blood flowing in the artificial blood vessel 21 is poured into the blood circulation device 10, and the blood circulation promoter is supplied into the artificial blood from the blood circulation promoter supply unit 13. In the irradiation unit 14, the artificial blood supplied with the blood circulation promoter was irradiated with visible light to circulate the artificial blood for 144 hours.

１４４時間経過後、人工血液の循環をやめて、人工血管２１内の人工血液を排出した後、人工血管２１の内壁に接着させた塊２２を採取し、その大きさを計測して、塊２２の大きさの変化を確認した。その結果、塊２２の大きさは、０．８７ｍｍ程度に減少しており、明らかに、塊２２が小さくなっていることが確認された。   After 144 hours, the circulation of the artificial blood is stopped and the artificial blood in the artificial blood vessel 21 is discharged. Then, the lump 22 adhered to the inner wall of the artificial blood vessel 21 is collected, and the size of the lump 22 is measured. The change in size was confirmed. As a result, the size of the lump 22 was reduced to about 0.87 mm, and it was clearly confirmed that the lump 22 was small.

（実施例７）
図１２に示すように、循環器２０に、全長３ｍ、直径４ｍｍの人工血管２１を接続して、常に、人工血管２１内に溶媒を循環させる簡易的な溶媒循環装置を作成した。その後、人工血管２１の一部を切断し、その内壁に、コレステロールと同じ物質で構成された大きさが１ｍｍの塊２２を、接着剤を用いて接着させて、もとの位置に縫合させた。さらに、直径３０μｍの人工血管２５を、複数本、縫合してバイパスを作り、仮想的な毛細血管を作製した。 (Example 7)
As shown in FIG. 12, an artificial blood vessel 21 having a total length of 3 m and a diameter of 4 mm was connected to the circulator 20 to create a simple solvent circulation device that constantly circulates the solvent in the artificial blood vessel 21. Thereafter, a part of the artificial blood vessel 21 was cut, and a lump 22 made of the same substance as cholesterol and having a size of 1 mm was adhered to the inner wall using an adhesive and sutured to the original position. . Further, a plurality of artificial blood vessels 25 having a diameter of 30 μm were sutured to create a bypass, thereby producing a virtual capillary blood vessel.

その後、人工血管２１内に溶媒として人工血液を流し込み、循環の流量を安定させた後、塊２２を接着して縫合させた人工血管２１の循環方向上流部に、図１２に示すように、血液循環装置１０を接続し、人工血管２１内を流れる人工血液の一部を血液循環装置１０内に流し込み、血液循環促進剤供給部１３から、人工血液内に血液循環促進剤を供給すると共に、光照射部１４で、血液循環促進剤を供給した人工血液に可視光を照射して、１４４時間人工血液を循環させた。   Thereafter, artificial blood is poured into the artificial blood vessel 21 as a solvent to stabilize the circulation flow rate, and then blood is added to the upstream portion in the circulation direction of the artificial blood vessel 21 to which the mass 22 is bonded and sutured, as shown in FIG. The circulation device 10 is connected, a part of the artificial blood flowing in the artificial blood vessel 21 is poured into the blood circulation device 10, and the blood circulation promoter is supplied into the artificial blood from the blood circulation promoter supply unit 13. In the irradiation unit 14, the artificial blood supplied with the blood circulation promoter was irradiated with visible light to circulate the artificial blood for 144 hours.

１４４時間経過後、人工血液の循環をやめて、人工血管２１内の人工血液を排出した後、人工血管２１の内壁に接着させた塊２２を採取し、その大きさを計測して、塊２２の大きさの変化を確認するとともに、直径３０μｍの人工血管２５を縫合した部分の人工血管２５の接合部２６の詰まり程度を目視にて確認した。その結果、塊２２の大きさは、０．８８ｍｍ程度に減少しており、明らかに、塊２２が小さくなっていることが確認された。また、すべての接合部２６においてコレステロール等による詰まりは確認されなかった。   After 144 hours, the circulation of the artificial blood is stopped and the artificial blood in the artificial blood vessel 21 is discharged. Then, the lump 22 adhered to the inner wall of the artificial blood vessel 21 is collected, and the size of the lump 22 is measured. While confirming the change in size, the degree of clogging of the joint portion 26 of the artificial blood vessel 25 where the artificial blood vessel 25 having a diameter of 30 μm was sewn was visually confirmed. As a result, the size of the lump 22 was reduced to about 0.88 mm, and it was clearly confirmed that the lump 22 was small. Moreover, clogging due to cholesterol or the like was not confirmed in all the joint portions 26.

以上、本発明の実施の形態を説明したが、本発明はこれらに限られず、特許請求の範囲に記載の発明の要旨の範疇において様々に変更可能である。また、本発明は、実施段階ではその要旨を逸脱しない範囲で種々に変形することが可能である。さらに、上記実施形態に開示されている複数の構成要素を適宜組み合わせることにより種々の発明を形成できる。   As mentioned above, although embodiment of this invention was described, this invention is not restricted to these, In the category of the summary of the invention as described in a claim, it can change variously. In addition, the present invention can be variously modified without departing from the scope of the invention in the implementation stage. Furthermore, various inventions can be formed by appropriately combining a plurality of constituent elements disclosed in the embodiment.

本発明に関わる血液循環促進剤を説明する概念図The conceptual diagram explaining the blood circulation promoter concerning this invention 本発明に関わる血液循環促進剤を生体に注射した時の生体の血管内の状態を説明する概念図。The conceptual diagram explaining the state in the blood vessel of the biological body when the blood circulation promoter concerning this invention is injected into the biological body. 本発明に関わる血液循環促進剤を生体に注射した時の生体の血管内の状態を説明する概念図。The conceptual diagram explaining the state in the blood vessel of the biological body when the blood circulation promoter concerning this invention is injected into the biological body. 本発明に関わる血液循環促進医療システムを説明する概念図。The conceptual diagram explaining the blood circulation promotion medical system in connection with this invention. 本発明に関わる光照射装置の一例を説明する概念図。The conceptual diagram explaining an example of the light irradiation apparatus concerning this invention. 本発明に関わる血液循環装置を説明する概念図The conceptual diagram explaining the blood circulation apparatus in connection with this invention 本発明に関わる実施例１を説明する概念図。The conceptual diagram explaining Example 1 in connection with this invention. 本発明に関わる実施例２を説明する概念図。The conceptual diagram explaining Example 2 in connection with this invention. 本発明に関わる実施例３を説明する概念図。The conceptual diagram explaining Example 3 in connection with this invention. 本発明に関わる実施例４、５を説明する概念図。The conceptual diagram explaining Example 4 and 5 in connection with this invention. 本発明に関わる実施例６を説明する概念図。The conceptual diagram explaining Example 6 in connection with this invention. 本発明に関わる実施例７を説明する概念図。The conceptual diagram explaining Example 7 in connection with this invention.

符号の説明Explanation of symbols

１ 血液循環促進剤
２ 可動子
３ 分散剤
４ コレステロール
５ 光
６ 腕輪
７ 発光ダイオード
８ 光照射装置
１０ 血液循環装置
１１ 血液採取部
１１ａ 注射器
１２ 血液循環部
１２ａ 細管
１２ｂ 血液循環装置
１３ 血液循環促進剤供給部
１３ａ 収容部
１３ｂ 細管
１４ 光照射部
１４ａ 発光ダイオード
１４ｂ 固定基材
１５ 血液注入部
１５ａ 注射器
２０ 循環器
２１ 人工血管
２２ 塊
２３ 基材
２４ 発光ダイオード
２５ 人工血管
２６ 接合部 DESCRIPTION OF SYMBOLS 1 Blood circulatory promoter 2 Mover 3 Dispersant 4 Cholesterol 5 Light 6 Brace 7 Light emitting diode 8 Light irradiation apparatus 10 Blood circulator 11 Blood collection part 11a Syringe 12 Blood circulator 12a tubule 12b Blood circulator 13 Supply blood circulator Part 13a Housing part 13b Capillary tube 14 Light irradiation part 14a Light emitting diode 14b Fixing base material 15 Blood injection part 15a Syringe 20 Circulator 21 Artificial blood vessel 22 Mass 23 Base material 24 Light emitting diode 25 Artificial blood vessel 26 Joint part

Claims (9)

光の照射により自走するナノメートルオーダーの粒径を有する可動子と、
前記可動子を分散させるための分散剤と、
を備えることを特徴とする血液循環促進剤。 A mover having a particle size on the order of nanometers, which is self-propelled by light irradiation,
A dispersing agent for dispersing the mover;
A blood circulation promoter comprising: 前記可動子は球体、又は、楕円体の形状を備えることを特徴とする請求項１に記載の血液循環促進剤。   The blood circulation promoter according to claim 1, wherein the mover has a spherical or ellipsoidal shape. 前記分散剤は、弱アルカリで構成された医薬品であることを特徴とする請求項１または２に記載の血液循環促進剤。   The blood circulation promoter according to claim 1 or 2, wherein the dispersing agent is a pharmaceutical comprising a weak alkali. 前記分散剤には、心臓疾患用医薬品が含まれていることを特徴とする請求項１から３のいずれか１項に記載の血液循環促進剤。   The blood circulation promoter according to any one of claims 1 to 3, wherein the dispersant contains a drug for heart disease. 生体の血液を採取する血液採取手段と、
採取された血液を循環させる血液循環手段と、
前記血液循環手段に光の照射により自走するナノメートルオーダーの粒径を有する可動子が分散された血液循環促進剤を供給する血液循環促進剤供給手段と、
前記血液循環促進剤が供給された血液に光を照射する光照射手段と、
前記光照射手段で照射された血液を前記生体に注射する血液注射手段と、
を備えたことを特徴とする血液循環装置。 Blood collection means for collecting blood from a living body;
A blood circulation means for circulating the collected blood;
A blood circulation promoting agent supply means for supplying a blood circulation promoting agent in which a mover having a particle size of nanometer order that is self-propelled by irradiation of light to the blood circulation means is dispersed;
A light irradiation means for irradiating the blood supplied with the blood circulation promoter;
Blood injection means for injecting the blood irradiated by the light irradiation means into the living body;
A blood circulation device comprising: 前記可動子は球体、又は、楕円体の形状を備えることを特徴とする請求項５に記載の血液循環装置。   The blood circulation device according to claim 5, wherein the movable element has a spherical shape or an ellipsoidal shape. 前記分散剤は、弱アルカリで構成された医薬品であることを特徴とする請求項５または６に記載の血液循環装置。   The blood circulation device according to claim 5 or 6, wherein the dispersing agent is a medicine composed of weak alkali. 前記分散剤には、心臓疾患用医薬品が含まれていることを特徴とする請求項５から７のいずれか１項に記載の血液循環装置。   The blood circulation device according to any one of claims 5 to 7, wherein the dispersing agent contains a drug for heart disease. 光の照射により自走するナノメートルオーダーの粒径を有する可動子が分散された血液循環促進剤と、
前記血液循環促進剤に含まれる可動子に光エネルギーを供給する光照射装置と、
を備えたことを特徴とする血液循環促進医療システム。 A blood circulation promoting agent in which a mover having a particle size of nanometer order that is self-propelled by light irradiation is dispersed;
A light irradiation device for supplying light energy to the mover contained in the blood circulation promoter;
A blood circulation promoting medical system characterized by comprising:
JP2005285590A 2005-09-29 2005-09-29 Blood circulation promoter, blood-circulating apparatus and blood circulation-promoting medical system Pending JP2007091673A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005285590A JP2007091673A (en) 2005-09-29 2005-09-29 Blood circulation promoter, blood-circulating apparatus and blood circulation-promoting medical system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005285590A JP2007091673A (en) 2005-09-29 2005-09-29 Blood circulation promoter, blood-circulating apparatus and blood circulation-promoting medical system

Publications (1)

Publication Number Publication Date
JP2007091673A true JP2007091673A (en) 2007-04-12

Family

ID=37977791

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005285590A Pending JP2007091673A (en) 2005-09-29 2005-09-29 Blood circulation promoter, blood-circulating apparatus and blood circulation-promoting medical system

Country Status (1)

Country Link
JP (1) JP2007091673A (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059505A1 (en) * 1999-04-02 2000-10-12 Meiji Seika, Kaisha, Ltd. Inhibitors for vascular reconstriction after angioplasty
JP2001212250A (en) * 2000-02-01 2001-08-07 Japan Science & Technology Corp Light irradiation device for living organism
JP2005502618A (en) * 2001-06-04 2005-01-27 ザ・ジェネラル・ホスピタル・コーポレイション Methods for detecting and treating vulnerable plaque using photodynamic compounds
JP2005504008A (en) * 2001-05-02 2005-02-10 アメリカン バイオサイエンス、インコーポレイテッド Compositions and methods for treating hyperplasia
JP2005102930A (en) * 2003-09-30 2005-04-21 Terumo Corp Beam apparatus for improving skin blood flow
WO2005063113A1 (en) * 2003-05-01 2005-07-14 Keio University Intravascular diagnostic or therapeutic apparatus using high-intensity pulsed light
WO2005077407A1 (en) * 2004-01-16 2005-08-25 Barnes-Jewish Hospital Targeted atherosclerosis treatment

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059505A1 (en) * 1999-04-02 2000-10-12 Meiji Seika, Kaisha, Ltd. Inhibitors for vascular reconstriction after angioplasty
JP2001212250A (en) * 2000-02-01 2001-08-07 Japan Science & Technology Corp Light irradiation device for living organism
JP2005504008A (en) * 2001-05-02 2005-02-10 アメリカン バイオサイエンス、インコーポレイテッド Compositions and methods for treating hyperplasia
JP2005502618A (en) * 2001-06-04 2005-01-27 ザ・ジェネラル・ホスピタル・コーポレイション Methods for detecting and treating vulnerable plaque using photodynamic compounds
WO2005063113A1 (en) * 2003-05-01 2005-07-14 Keio University Intravascular diagnostic or therapeutic apparatus using high-intensity pulsed light
JP2005102930A (en) * 2003-09-30 2005-04-21 Terumo Corp Beam apparatus for improving skin blood flow
WO2005077407A1 (en) * 2004-01-16 2005-08-25 Barnes-Jewish Hospital Targeted atherosclerosis treatment

Similar Documents

Publication Publication Date Title
US11389171B2 (en) Integrated system for the infixion and retrieval of implants
US11759186B2 (en) Ductus side-entry and prosthetic disorder response systems
US20140163664A1 (en) Integrated system for the ballistic and nonballistic infixion and retrieval of implants with or without drug targeting
US20160051806A1 (en) Ductus side-entry jackets and prosthetic disorder response systems
US11642210B2 (en) Lasso filter tipped microcatheter for simultaneous rotating separator, irrigator for thrombectomy and method for use
US20060100553A1 (en) Heart valve decalcification method and apparatus
KR102503994B1 (en) Devices and methods for injectable vascular sclerofoams using a carrier matrix and uses thereof
Marosfoi et al. Shear-activated nanoparticle aggregates combined with temporary endovascular bypass to treat large vessel occlusion
Johansen et al. A new technique for modeling of hematogenous osteomyelitis in pigs: inoculation into femoral artery
CN106232152A (en) Use sclerotherapy compositions and the device of photo-hardening glue
Selmi et al. Comparison of retrograde intrarenal surgery and percutaneous nephrolithotomy methods in treatment of upper calyceal stones of 10–20 mm
Fourneau et al. An improved model of acute liver failure based on transient ischemia of the liver
JP2007091673A (en) Blood circulation promoter, blood-circulating apparatus and blood circulation-promoting medical system
US20220273312A1 (en) Vascular valves and servovalves - and prosthetic disorder response systems
Mickelson et al. Evaluation of a microvascular anastomotic coupler for end‐to‐side arterial and venous anastomosis for feline renal transplantation
Alexandrescu Angiosomes applications in critical limb ischemia
Yuen Techniques of external monitoring of buried free flaps
Venouziou et al. Supplemental graft fixation for distal radius vascularized bone graft
Lee et al. In vivo evaluation of histopathologic findings of vascular damage after mechanical thrombectomy with the Tromba device in a canine model of cerebral infarction
Eden ATHERO52, A Proof of Concept Device Design to Remove and Treat Atherosclerosis with a Non-Invasive Surgical Approach
Liu et al. Construction of a canine model with acute type B aortic dissection using a self-made pressure-driven flow device
WO2014049821A1 (en) Medical system
Mattrey Are cerebral emboli real when perfluorocarbon emulsion (AF0144) is used in cardiac surgery?
Melville et al. Reconstruction of Post-Traumatic Maxillary Ridges Using a Radial Forearm Free Flap and Allogeneic Tissue-Engineered Bone Grafts
Vogt et al. Evidence of an autoregulatory mechanism of regional bone blood flow at hypotension

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100723

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101116